J&J's $21.3B bid for orthopedic devicemaker Synthes nearly done

Johnson & Johnson's ($JNJ) $21.3 billion bid to buy Swiss orthopedic device maker Synthes is finally reaching the regulatory finish line.

The Associated Press reported that the Federal Trade Commission will approve the deal, as long as J&J agrees to sell its DVR system for surgically treating wrist fractures to Biomet. Earlier this year, the company decided to sell its DePuy global trauma business to Biomet for $280 million to satisfy European regulatory concerns about the deal. The EU granted approval for the sale in April as a result.

The merger could close as early as this week, according to reports, marking the expected close of what was FierceMedicalDevice's top medical device deal of 2011 (and J&J's biggest purchase ever), more than a year after it was first announced. J&J will also become the biggest competitor in the $5.5 billion trauma device market.

- here's The Associated Press story

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.